ProMis Neurosciences, Inc.

92 articles with ProMis Neurosciences, Inc.

• 

  Now, What’s Next in Alzheimer's? For Biogen and Eisai, Another Phase III Trial

  3/22/2019

  The debacle raised three broad questions: What will Biogen do next? Is the amyloid theory of Alzheimer’s now dead? And what else is going on in the Alzheimer’s drug development arena?

• Aducanumab Failure: Selectivity for the Toxic Oligomer is Essential to Treating Root Cause of Alzheimer's Disease

  3/21/2019

  Discontinued aducanumab phase 3 studies emphasize urgent need for therapies that target the toxic oligomer with exacting precision

• ProMIS Neurosciences to Present Data for Potential Best-in-Class Antibody Candidates for Parkinson's Disease at AD/PD 2019 Conference

  3/19/2019

  ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, will present data for new antibody candidates that show stringent selectivity for the toxic forms of alpha-synuclein, considered a root cause of Parkinson's disease

• ProMIS Neurosciences Announces Fiscal Year 2018 Annual Results

  3/15/2019

  ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced its operational and financial results for the year ended December 31, 2018.

• ProMIS Neurosciences Adds Pharmaceutical Leader Timothy Rothwell to Board of Advisors

  2/21/2019

  Former Sanofi U.S. Chairman to provide guidance and assistance to ProMIS business development strategies and partnering plans

• Selectivity for the Toxic Oligomer Essential to Treating Root Cause of Alzheimer's Disease

  1/31/2019

  Discontinued crenezumab phase 3 studies underscore urgent need for therapies that target the toxic oligomer with extraordinary precision

• ProMIS Neurosciences to Participate in NobleCon15 and CanTech Investment Conferences

  1/17/2019

  Company to showcase its innovative Alzheimer's, Parkinson's and ALS programs

• ProMIS Neurosciences to Present at Sachs Associates Neuroscience Innovation Forum and China Focus@JPMWeek

  12/18/2018

  ProMIS to showcase its Alzheimer's, Parkinson's and ALS programs at notable biotech investor events

• ProMIS Neurosciences Appoints Renowned Neuroscientist, Dr. Rudolph Tanzi, to Scientific Advisory Board

  12/17/2018

  Dr. Rudolph Tanzi is a neuroscientist and geneticist with scientific expertise in Alzheimer's disease and brain health.

• ProMIS Neurosciences Issues Year-to Date Update, Highlighting 2018 Accomplishments

  11/20/2018

  Development of therapeutic antibodies for Alzheimer's disease, Parkinson's disease and ALS are top priorities for drug development and potential partnering

• ProMIS Neurosciences Announces Third Quarter 2018 Results

  11/13/2018

  ProMIS Neurosciences, Inc. today announced its operational and financial results for the three and nine months ended September 30, 2018.

• ProMIS Neurosciences Discusses Critical Importance of Selectively Targeting the Root Cause of Alzheimer's Disease

  11/6/2018

  Narrated white paper reveals lessons learned from 15 years of drug development; pressing need to selectively target the toxic oligomer.

• ProMIS Neurosciences Identifies Novel Targets on Tau Protein Involved in the Development of Alzheimer's Disease and Other Dementias

  10/31/2018

  ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced the identification of novel targets on misfolded, pathological forms of tau.

• ProMIS Neurosciences Identifies Novel Antibody Drug Candidates for Parkinson's Disease

  10/11/2018

  Unique discovery platform generates new antibody candidates that block a root cause of Parkinson's Disease

• ProMIS Neurosciences to Present at Extraordinary Futures Investment Conference

  9/17/2018

  The conference is being held on September 19-20, 2018 at the Vancouver Convention Centre East in Vancouver, British Columbia.

• ProMIS Neurosciences Appoints James Kupiec, MD as Chief Medical Officer

  9/13/2018

  Dr. Kupiec to leverage neurodegenerative experience from prior senior positions at Pfizer and Sanofi-Synthelabo

• ProMIS Neurosciences Issues Narrated Overview of Second Quarter 2018 Results

  8/29/2018

  ProMIS Neurosciences, Inc. today announced it has issued a narrated overview of second quarter 2018 operational results.

• ProMIS Neurosciences to Present at 20th Annual Global Investment Conference

  8/22/2018

  ProMIS Neurosciences, Inc. announced that it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference

• ProMIS Neurosciences Oligomer Selective Antibody Therapeutic for Alzheimer's Disease, PMN310, Shows Potential for Improved Safety Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies in Clinical Development

  8/21/2018

  Lack of PMN310 binding to amyloid deposits in Alzheimer's brain tissue may eliminate dose-limiting brain swelling seen with BAN2401 and aducanumab

• ProMIS Neurosciences Announces Second Quarter 2018 Results

  8/14/2018

  The net loss for the three months ended June 30, 2018 was $2,214,861, compared to a net loss of $1,903,396 for the three months ended June 30, 2017.